Episurf Medical has become an approved supplier to Spire Healthcare, one of the UK’s largest independent hospital providers
Episurf Medical (NASDAQ: EPIS B) has become an approved supplier to Spire Healthcare, one of the UK’s largest independent hospital providers with 39 hospitals, 10 clinics and two specialist cancer care centres across England, Wales and Scotland. The decision has been made following a review process.
“We are very pleased that, with the support from some of the UK’s leading surgeons, Episealer® has received approval from Spire Healthcare as a new treatment method for focal cartilage and bone damages of the knee”, says Pål Ryfors, CEO Episurf Medical. “Spire Healthcare delivers a very high standard of care for both private and NHS patients across the UK. We look forward to offering the Episealer® to suitable patients, enabling them to benefit from our technology which can help them to get back to a pain-free lifestyle”, concludes Ryfors.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel: +46 (0) 709 62 36 69
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on 20 July 2017.